加载中
Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical development phase, dedicated to discovering, advancing, and commercializing pharmaceutical treatments for solid tumor cancers. The company's primary experimental compound, INT230-6, is presently undergoing Phase 2 clinical trials. This investigational drug targets a range of difficult-to-treat solid tumors, including those affecting the pancreas, colon, bile duct, as well as squamous cell, sarcoma, breast, and liver cancers. Intensity Therapeutics has formed strategic collaborations with major pharmaceutical companies and research institutions: A partnership with Merck Sharpe & Dohme Corp. focuses on evaluating INT230-6 in conjunction with Keytruda for advanced pancreatic, colon, squamous cell, and bile duct malignancies. Another collaboration with Bristol-Myers Squibb Company is dedicated to studying INT230-6 combined with Yervoy in patients suffering from advanced liver, breast, and sarcoma cancers. Furthermore, the company is working with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research on a randomized controlled Phase II neoadjuvant study of INT230-6 for women diagnosed with early-stage breast cancer. Established in 2012, Intensity Therapeutics maintains its corporate headquarters in Westport, Connecticut.
前收盘价
US$3.63
−US$0.05 · -1.36%
盘中时间采用ET。市场数据可能有所延迟。
Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical development phase, dedicated to discovering, advancing, and commercializing pharmaceutical treatments for solid tumor cancers. The company's primary experimental compound, INT230-6, is presently undergoing Phase 2 clinical trials. This investigational drug targets a range of difficult-to-treat solid tumors, including those affecting the pancreas, colon, bile duct, as well as squamous cell, sarcoma, breast, and liver cancers. Intensity Therapeutics has formed strategic collaborations with major pharmaceutical companies and research institutions: A partnership with Merck Sharpe & Dohme Corp. focuses on evaluating INT230-6 in conjunction with Keytruda for advanced pancreatic, colon, squamous cell, and bile duct malignancies. Another collaboration with Bristol-Myers Squibb Company is dedicated to studying INT230-6 combined with Yervoy in patients suffering from advanced liver, breast, and sarcoma cancers. Furthermore, the company is working with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research on a randomized controlled Phase II neoadjuvant study of INT230-6 for women diagnosed with early-stage breast cancer. Established in 2012, Intensity Therapeutics maintains its corporate headquarters in Westport, Connecticut.
日内区间
当前US$3.63
52周区间
当前US$3.63
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
29
偏贵
情绪
44
多空交织
风险
89
极高风险
动量
34
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical development phase, dedicated to discovering, advancing, and commercializing pharmaceutical treatments for solid tumor cancers. The company's primary experimental compound, INT230-6, is presently undergoing Phase 2 clinical trials. This investigational drug targets a range of difficult-to-treat solid tumors, including those affecting the pancreas, colon, bile duct, as well as squamous cell, sarcoma, breast, and liver cancers. Intensity Therapeutics has formed strategic collaborations with major pharmaceutical companies and research institutions: A partnership with Merck Sharpe & Dohme Corp. focuses on evaluating INT230-6 in conjunction with Keytruda for advanced pancreatic, colon, squamous cell, and bile duct malignancies. Another collaboration with Bristol-Myers Squibb Company is dedicated to studying INT230-6 combined with Yervoy in patients suffering from advanced liver, breast, and sarcoma cancers. Furthermore, the company is working with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research on a randomized controlled Phase II neoadjuvant study of INT230-6 for women diagnosed with early-stage breast cancer. Established in 2012, Intensity Therapeutics maintains its corporate headquarters in Westport, Connecticut.
日内区间
当前US$3.63
52周区间
当前US$3.63
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 2.6万 USD | — | 14.7万 USD | — | — |
| 毛利 | −2.6万 USD | — | −14.7万 USD | — | — |
| 研究与开发 | 678.5万 USD | 1049.6万 USD | 478.6万 USD | 513.2万 USD | 585.65万 USD |
| 销售、一般及管理费用 | 518.7万 USD | 608.9万 USD | 338.6万 USD | 241.8万 USD | 214万 USD |
| 营业费用 | 1197.2万 USD | 1658.5万 USD | 817.2万 USD | 755万 USD | 801.37万 USD |
| 利息收入 | 18万 USD | 31.4万 USD | 32.4万 USD | 2481 USD | 2609 USD |
| 利息支出 | — | — | 30.5万 USD | 8.18万 USD | 1.68万 USD |
| 折旧和摊销 | — | — | 14.7万 USD | 17.9万 USD | — |
| 营业利润 | −1197.2万 USD | −1658.5万 USD | −831.9万 USD | −755万 USD | −801.37万 USD |
| 净利润 | −1160.6万 USD | −1626.8万 USD | −1053.8万 USD | −758.2万 USD | −789.56万 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$11.00
上涨空间 203.03%评级样本有限，仅3项
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2026年2月19日 | 1:25 | — | — |
已生效 2026年2月19日
1:25
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
